Atossa Genetics Inc. Aktie News

Amid the rise of the digital innovation space, investors may want to consider biotech stocks to buy. Fundamentally, a rotation into the sector may occur, boding well for the ecosystem before the summer rally kicks off.

With innovation, millions of retiring baby boomers, demand for better care, patent cliffs, gene-editing, massive interest in weight-loss treatments, and an increase in mergers, biotech stocks to buy have a good deal of upside ahead. Look at weight loss stocks, like Viking Therapeutics (NASDAQ: VKTX ), for example.

Atossa Therapeutics Inc (NASDAQ:ATOS) has given the last patient's final dose in its Karisma-Endoxifen clinical trial, aimed at reducing the chances of breast cancer. Some 240 people took part in the phase two trial, which began in November, Atossa Therapeutics said on Wednesday.

SEATTLE, May 15, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that the last patient in the Company's Karisma-Endoxifen clinical trial received their final dose of study medication. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focu...

Atossa Therapeutics Inc (NASDAQ:ATOS) continued to advance the development of its lead clinical asset (Z)-endoxifen to prevent and treat breast cancer in the first quarter of 2024, exiting the quarter in a strong cash position with no debt. “The first quarter of 2024 was a period of significant progress for our company,” Dr Steven Quay, CEO of the clinical-stage biopharmaceutical company said i...

SEATTLE, May 13, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced financial results for the fiscal quarter ended March 31, 2024, and provides an update on recent company developments. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus...

Under-the-radar penny stocks can be some of the most rewarding investments on the market. Look at ACADIA Pharmaceuticals (NASDAQ: ACAD ), for example.

Atossa Therapeutics Inc (NASDAQ:ATOS) has welcomed new guidelines released by the US Preventative Services Task Force that recommend women begin breast cancer screening starting at age 40. The biopharmaceutical company targeting breast cancer with its lead asset (Z)-endoxifen highlighted that the change to the recommended age comes in response to rising breast cancer rates among younger women a...